A phase III randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with preserved Ejection Fraction (HFpEF).

Project: Other project

StatusActive
Effective start/end date10/17/1710/16/20

Funding

  • Boehringer Ingelheim Pharmaceuticals: $8,076.92